APA

Sheppard M., Bronstein M. D., Freda P., Serri O., De Marinis L., Naves L., Rozhinskaya L., Hermosillo Reséndiz K., Ruffin M., Chen Y. & Colao A. (20160407). Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. : Pituitary.

Chicago

Sheppard Michael, Bronstein Marcello D, Freda Pamela, Serri Omar, De Marinis Laura, Naves Luciana, Rozhinskaya Liudmila, Hermosillo Reséndiz Karina, Ruffin Matthieu, Chen YinMiao and Colao Annamaria. 20160407. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. : Pituitary.

Harvard

Sheppard M., Bronstein M. D., Freda P., Serri O., De Marinis L., Naves L., Rozhinskaya L., Hermosillo Reséndiz K., Ruffin M., Chen Y. and Colao A. (20160407). Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. : Pituitary.

MLA

Sheppard Michael, Bronstein Marcello D, Freda Pamela, Serri Omar, De Marinis Laura, Naves Luciana, Rozhinskaya Liudmila, Hermosillo Reséndiz Karina, Ruffin Matthieu, Chen YinMiao and Colao Annamaria. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. : Pituitary. 20160407.